CN102643233B - 用于治疗癌症的包含苯醌的安沙霉素类似物 - Google Patents

用于治疗癌症的包含苯醌的安沙霉素类似物 Download PDF

Info

Publication number
CN102643233B
CN102643233B CN201210093005.4A CN201210093005A CN102643233B CN 102643233 B CN102643233 B CN 102643233B CN 201210093005 A CN201210093005 A CN 201210093005A CN 102643233 B CN102643233 B CN 102643233B
Authority
CN
China
Prior art keywords
hydrogen
acid
alkyl
salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201210093005.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN102643233A (zh
Inventor
J·亚当斯
Y·高
A·T·乔治斯埃文格利诺斯
L·格雷尼尔
R·H·朴
J·R·波特
J·L·赖特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Infinity Discovery Inc
Original Assignee
Infinity Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34744040&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102643233(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Infinity Discovery Inc filed Critical Infinity Discovery Inc
Priority claimed from CN2004800386529A external-priority patent/CN1898212B/zh
Publication of CN102643233A publication Critical patent/CN102643233A/zh
Application granted granted Critical
Publication of CN102643233B publication Critical patent/CN102643233B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201210093005.4A 2003-12-23 2004-12-23 用于治疗癌症的包含苯醌的安沙霉素类似物 Expired - Fee Related CN102643233B (zh)

Applications Claiming Priority (25)

Application Number Priority Date Filing Date Title
US53208003P 2003-12-23 2003-12-23
US60/532080 2003-12-23
US60/532,080 2003-12-23
US54014204P 2004-01-29 2004-01-29
US60/540,142 2004-01-29
US60/540142 2004-01-29
US54738104P 2004-02-23 2004-02-23
US60/547381 2004-02-23
US60/547,381 2004-02-23
US56171804P 2004-04-12 2004-04-12
US60/561,718 2004-04-12
US60/561718 2004-04-12
US56756504P 2004-05-03 2004-05-03
US60/567,565 2004-05-03
US60/567565 2004-05-03
US60628304P 2004-09-01 2004-09-01
US60/606283 2004-09-01
US60/606,283 2004-09-01
US62628604P 2004-11-09 2004-11-09
US60/626,286 2004-11-09
US60/626286 2004-11-09
US63285804P 2004-12-03 2004-12-03
US60/632858 2004-12-03
US60/632,858 2004-12-03
CN2004800386529A CN1898212B (zh) 2003-12-23 2004-12-23 用于治疗癌症的包含苯醌的安沙霉素类似物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2004800386529A Division CN1898212B (zh) 2003-12-23 2004-12-23 用于治疗癌症的包含苯醌的安沙霉素类似物

Publications (2)

Publication Number Publication Date
CN102643233A CN102643233A (zh) 2012-08-22
CN102643233B true CN102643233B (zh) 2015-11-25

Family

ID=34744040

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201210093005.4A Expired - Fee Related CN102643233B (zh) 2003-12-23 2004-12-23 用于治疗癌症的包含苯醌的安沙霉素类似物

Country Status (15)

Country Link
US (13) US7282493B2 (enExample)
EP (2) EP1716119B1 (enExample)
JP (2) JP4869077B2 (enExample)
KR (1) KR101154351B1 (enExample)
CN (1) CN102643233B (enExample)
AU (1) AU2004309395C1 (enExample)
BR (1) BRPI0418147A (enExample)
CA (1) CA2547343C (enExample)
DK (1) DK1716119T3 (enExample)
ES (1) ES2409351T3 (enExample)
IL (2) IL175911A (enExample)
NO (1) NO337933B1 (enExample)
PT (1) PT1716119E (enExample)
RU (1) RU2484086C9 (enExample)
WO (1) WO2005063714A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090197852A9 (en) * 2001-08-06 2009-08-06 Johnson Robert G Jr Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
US7282493B2 (en) 2003-12-23 2007-10-16 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
US20060019941A1 (en) * 2003-12-23 2006-01-26 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
BRPI0517268A (pt) * 2004-11-02 2008-10-07 Conforma Therapeutics Corp método para tratar uma forma de leucemia linfocìtica crÈnica
US10252088B2 (en) 2004-12-02 2019-04-09 Obagi Cosmeceuticals Llc Topical compositions and methods of manufacturing them in specifically treated steel vessels
WO2006098761A2 (en) 2005-03-11 2006-09-21 The Regents Of The University Of Colorado Hsp90 inhibitors, methods of making and uses therefor
US11457813B2 (en) 2005-03-29 2022-10-04 Martin W. Roche Method for detecting body parameters
CA2604473A1 (en) * 2005-04-29 2006-11-09 Kosan Biosciences Incorporated Method of treating multiple myeloma using 17-aag or 17-ag or a prodrug of either
GB0517886D0 (en) * 2005-09-02 2005-10-12 Biotica Tech Ltd Novel compounds
US20090042847A1 (en) * 2005-11-23 2009-02-12 Kosan Biosciences Incorporated 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
WO2007098229A2 (en) * 2006-02-21 2007-08-30 Michigan State University Geldanamycin derivatives and method of use thereof
GB0606548D0 (en) * 2006-03-31 2006-05-10 Biotica Tech Ltd Novel compounds and methods for their production
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
FR2907453B1 (fr) 2006-10-24 2008-12-26 Sanofi Aventis Sa Nouveaux derives du fluorene,compositions les contenant et utilisation
KR20090075856A (ko) * 2006-11-09 2009-07-09 바이오티카 테크놀로지 리미티드 신규한 화합물 및 이의 제조방법
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
EP2121957A4 (en) * 2007-01-26 2010-11-10 Kosan Biosciences Inc MACROLACTAMES OBTAINED BY MODIFIED BIOSYNTHESIS
BRPI0810835A2 (pt) * 2007-04-12 2015-06-16 Infinity Discovery Inc Formulações de hidroquinona ansamicina
WO2008154441A1 (en) * 2007-06-07 2008-12-18 Joyant Pharmaceuticals, Inc. Methods for preparing diazonamides
US8551964B2 (en) 2007-08-23 2013-10-08 The Regents Of The University Of Colorado Hsp90 inhibitors with modified toxicity
EP2348845A4 (en) * 2008-10-15 2013-01-23 Infinity Pharmaceuticals Inc ANSAMYCIN HYDROQUINONE COMPOSITIONS
US8669289B2 (en) * 2009-04-24 2014-03-11 The Jackson Laboratory Methods and compositions relating to hematologic malignancies
WO2010135426A1 (en) * 2009-05-19 2010-11-25 Infinity Pharmaceuticals, Inc. Methods of treating liposarcoma
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
US20110118298A1 (en) * 2009-11-13 2011-05-19 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
WO2013074695A1 (en) 2011-11-14 2013-05-23 The Regents Of The University Of Colorado, A Body Corporate Hsp90 inhibitors with modified toxicity
CN108028172B (zh) * 2015-09-19 2022-07-29 应用材料公司 使用硅氢加成钝化的表面选择性原子层沉积
US10052304B2 (en) * 2015-10-12 2018-08-21 University Of Iowa Research Foundation Compositions and methods for cancer therapy
JP7217700B2 (ja) 2016-09-13 2023-02-03 アラーガン、インコーポレイテッド 安定化非タンパク質クロストリジウム毒素組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4421688A (en) * 1981-09-17 1983-12-20 Takeda Chemical Industries, Ltd. Macbecin derivatives
CN1074937A (zh) * 1992-01-06 1993-08-04 弗埃塞股份有限公司 4，5-二氢格尔德霉素及其氢醌的制备和用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US120578A (en) 1871-11-07 Improvement in letter-boxes
US123640A (en) 1872-02-13 Improvement in tab-plates of buckles
US745718A (en) * 1903-04-25 1903-12-01 Owen Thomas Dougherty Weight-indicating sliding and spring support for vehicle-bodies.
GB210611A (en) * 1923-01-16 1924-02-07 Clarence Hancock Improved means of heating garden propagating frames, foster mothers and the like
US3595955A (en) 1969-03-26 1971-07-27 Upjohn Co Geldanamycin and process for producing same
JPS5470299A (en) * 1977-11-14 1979-06-05 Takeda Chem Ind Ltd Production of maytansine derivative
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
GB2106111B (en) 1981-09-17 1985-11-06 Takeda Chemical Industries Ltd Macbecin derivatives and their production
US4762857A (en) * 1986-05-30 1988-08-09 E. I. Du Pont De Nemours And Company Trehalose as stabilizer and tableting excipient
ZA878877B (en) 1986-11-29 1988-05-24 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Treatment of diseases caused by viruses
US5397584A (en) * 1992-12-09 1995-03-14 Mccormick & Company, Inc. Process for preparing stabilized, partially-dehydrated aromatic plant products
US5387584A (en) 1993-04-07 1995-02-07 Pfizer Inc. Bicyclic ansamycins
EP0706516A1 (en) * 1993-06-29 1996-04-17 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
US5932566A (en) 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
WO1996040265A1 (en) 1995-06-07 1996-12-19 The Regents Of The University Of California Stabilization of polynucleotide complexes
US5968921A (en) 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
MY120063A (en) 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
WO1999051223A1 (en) 1998-04-03 1999-10-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
EP1098666B1 (en) 1998-07-17 2013-01-16 The United States of America, represented by the Secretary, Department of Health and Human Services Water-soluble drugs and methods for their production
US6174875B1 (en) 1999-04-01 2001-01-16 University Of Pittsburgh Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
US6887853B2 (en) 2000-06-29 2005-05-03 The Trustees Of Boston University Use of geldanamycin and related compounds for treatment of fibrogenic disorders
US6946456B2 (en) 2000-07-28 2005-09-20 Sloan-Kettering Institute For Cancer Research Methods for treating cell proliferative disorders and viral infections
PT1373215E (pt) * 2001-03-30 2006-12-29 Uni S Of A R By The S D Of H H Derivado de geldanamicina e metodo de tratamento de cancro utilizando o mesmo
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
JP2005515164A (ja) * 2001-08-06 2005-05-26 コーサン バイオサイエンシーズ， インコーポレイテッド ベンゾキノンアンサマイシン
EP1420747A4 (en) 2001-08-06 2010-06-02 Kosan Biosciences Inc ANSAMYCIN BENZOQUINONE
JP2005504086A (ja) 2001-09-24 2005-02-10 コンフォーマ セラピューティクス コーポレーション １７−アリルアミノゲルダナマイシン（１７−ａａｇ）および他のアンサマイシン類を製造する方法
EP1519735A4 (en) * 2001-12-12 2006-01-11 Conforma Therapeutic Corp ASSAYS AND DEVICES FOR DETERMINING AND MODULATING HSP90 BINDING ACTIVITY
US7465718B2 (en) * 2002-02-08 2008-12-16 Conforma Therapeutics Corporation Ansamycins having improved pharmacological and biological properties
TW200303363A (en) 2002-02-25 2003-09-01 Upjohn Co Process to prepare and isolate geldanamycin
CN101912601B (zh) 2002-06-21 2012-08-29 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
CA2518836A1 (en) 2003-03-13 2004-09-30 Conforma Therapeutics Corporation Drug formulations having long and medium chain triglycerides
US20060019941A1 (en) 2003-12-23 2006-01-26 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
US7282493B2 (en) 2003-12-23 2007-10-16 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
JP2007530596A (ja) 2004-03-26 2007-11-01 バン アンデル リサーチ インスティチュート ゲルダナマイシンおよび誘導体はガン浸潤を阻害し、新規な標的を同定する
WO2006098761A2 (en) 2005-03-11 2006-09-21 The Regents Of The University Of Colorado Hsp90 inhibitors, methods of making and uses therefor
EP1906950A4 (en) 2005-06-21 2008-09-24 Infinity Discovery Inc ANSAMYCIN FORMULATIONS AND METHODS OF USE
KR20080027896A (ko) 2005-06-29 2008-03-28 교와 핫꼬 고교 가부시끼가이샤 벤제노이드 안사마이신 유도체
CN101360492A (zh) 2005-12-01 2009-02-04 康福玛医药公司 含安莎霉素的组合物
PE20081506A1 (es) 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
BRPI0810835A2 (pt) 2007-04-12 2015-06-16 Infinity Discovery Inc Formulações de hidroquinona ansamicina
US9907242B2 (en) 2016-02-18 2018-03-06 Seminis Vegetable Seeds, Inc. Pepper hybrid SV5873HE

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4421688A (en) * 1981-09-17 1983-12-20 Takeda Chemical Industries, Ltd. Macbecin derivatives
CN1074937A (zh) * 1992-01-06 1993-08-04 弗埃塞股份有限公司 4，5-二氢格尔德霉素及其氢醌的制备和用途

Also Published As

Publication number Publication date
US8703755B2 (en) 2014-04-22
IL175911A0 (en) 2006-10-05
IL206984A0 (en) 2011-07-31
US7375217B2 (en) 2008-05-20
US7579337B2 (en) 2009-08-25
US20050288269A1 (en) 2005-12-29
US8003634B2 (en) 2011-08-23
IL206984A (en) 2015-02-26
US7691840B2 (en) 2010-04-06
US7282493B2 (en) 2007-10-16
NO337933B1 (no) 2016-07-11
US20050227955A1 (en) 2005-10-13
NO20062707L (no) 2006-09-11
HK1097410A1 (en) 2007-06-22
RU2484086C2 (ru) 2013-06-10
JP5313308B2 (ja) 2013-10-09
AU2004309395A1 (en) 2005-07-14
JP2011225614A (ja) 2011-11-10
ES2409351T3 (es) 2013-06-26
DK1716119T3 (da) 2013-06-10
US20090088414A1 (en) 2009-04-02
RU2006126797A (ru) 2008-01-27
US20090069280A1 (en) 2009-03-12
EP1716119B1 (en) 2013-03-06
US20090208590A1 (en) 2009-08-20
PT1716119E (pt) 2013-06-04
US20090062250A1 (en) 2009-03-05
US20090253653A1 (en) 2009-10-08
US20060014731A1 (en) 2006-01-19
CN102643233A (zh) 2012-08-22
US20090209549A1 (en) 2009-08-20
US7608613B2 (en) 2009-10-27
EP2492261B1 (en) 2015-02-18
US7361647B2 (en) 2008-04-22
IL175911A (en) 2012-01-31
US7767662B2 (en) 2010-08-03
US20130203724A1 (en) 2013-08-08
BRPI0418147A (pt) 2007-04-17
WO2005063714A1 (en) 2005-07-14
EP2492261A1 (en) 2012-08-29
CA2547343A1 (en) 2005-07-14
KR101154351B1 (ko) 2012-06-15
KR20060132660A (ko) 2006-12-21
CA2547343C (en) 2013-05-14
JP4869077B2 (ja) 2012-02-01
US7566706B2 (en) 2009-07-28
US8252779B2 (en) 2012-08-28
US20060019939A1 (en) 2006-01-26
JP2007528875A (ja) 2007-10-18
AU2004309395C1 (en) 2012-10-04
AU2004309395B2 (en) 2011-10-06
US20120058982A1 (en) 2012-03-08
US20110086110A1 (en) 2011-04-14
EP1716119A1 (en) 2006-11-02
US7833997B2 (en) 2010-11-16
RU2484086C9 (ru) 2013-08-20
US7767663B2 (en) 2010-08-03

Similar Documents

Publication Publication Date Title
CN102643233A (zh) 用于治疗癌症的包含苯醌的安沙霉素类似物
JP2011225614A5 (enExample)
US20060019941A1 (en) Analogs of benzoquinone-containing ansamycins and methods of use thereof
CN1898212B (zh) 用于治疗癌症的包含苯醌的安沙霉素类似物
MXPA06007120A (en) Analogs of benzoquinone-containing ansamycins for the treatment of cancer
HK1097410B (en) Analogs of benzoquinone-containing ansamycins for the treatment of cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20151125

Termination date: 20161223

CF01 Termination of patent right due to non-payment of annual fee